Navigation Links
Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
Date:10/29/2007

this disease.

About Coley Pharmaceutical Group

Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders and to enhance the effectiveness of vaccines. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development either independently or with partners, and has additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi- aventis, GlaxoSmithKline, Merck, Novartis and the United States government. For further information on Coley Pharmaceutical Group please visit http://www.coleypharma.com.

Safe Harbor Statement

Certain statements in this news release concerning Coley's business are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the safety and tolerability of CPG 52364 for the treatment of Systemic Lupus Erythematosus (SLE); confirmation of TLR7/8/9 as a target for SLE; ; Coley's ability to enroll subjects in a Phase I clinical trial of CPG 52364; and, the timing of results of a Phase I clinical trial with CPG 52364. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Coley might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of product development; uncertainties as to the future success of ongoing and planned clinical trials; the risk that results from early stage clinical trials may not be indicative of results in later stage trials; the unp
'/>"/>

SOURCE Coley Pharmaceutical Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...,Nov.23/PRNewswire-USNewswire/--FebeDurango-Rueda,...oparticipatinginaschemetodefraudtheExport-ImportBa...announcedAssistantAttorneyGeneraloftheCriminalDivi....GratacosoftheEx-ImBank,OfficeoftheInspectorGenera...obertsinU.S.DistrictCourtinWashingtontoaone-countc...
(Date:11/23/2009)...s.,Nov.23/PRNewswire-FirstCall/--BostonScientificC...ePiperJaffrayHealthCareConference,December1-2. ,...SamLeno,ExecutiveVicePresidentandChiefFinancialOff...CompanyonTuesday,December1st,beginningatapproximat...willbeavailabletoallinterestedpartiesatBostonScien...
(Date:11/23/2009)...Calif.,Nov.23/PRNewswire-FirstCall/--DURECTCorpora...efFinancialOfficer,andJoeStauffer,ChiefMedicalOffi...lthCareConferenceonTuesday,December1at3:30pmEaster...telinNewYorkCity. ,, (Logo: http://www.newscom....sthelivepresentationviatheinternet,pleasegotothedi...
Breaking Medicine Technology:Colombian National Pleads Guilty to Role in Defrauding the Export-Import Bank of the United States of More Than $1 Million 2DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference 2US Government Places 6 1 Million USD Orders Related to Precise Match on Card 28TM 29 for Cyber Security Programs 9217 1US Government Places 6 1 Million USD Orders Related to Precise Match on Card 28TM 29 for Cyber Security Programs 9217 2UK Identity and Passport Service and IBM Sign 7 year National Biometric Identity Service 28NBIS 29 Contract 9215 1UK Identity and Passport Service and IBM Sign 7 year National Biometric Identity Service 28NBIS 29 Contract 9215 2Simple Steps Deliver Relief for Tennis Elbow 51399 1
...- Phase IIb study examines efficacy and safety of ...ive adults with HIV-1 -, MEXICO CITY, Aug. 5 New...provides additional information on the safety and,...stigational,non-nucleoside reverse transcriptase i...py in treatment-naive adults. These findings were,...
...CAMBRIDGE, Mass., Aug. 5 Tolerx, Inc., a,biopharm...elopment of novel,therapies for the treatment of i...ntech, a collaborator, has moved a modified versio...dy, into a phase 1 clinical trial,that has begun e...g the,safety and tolerability of both single and m...
Other Medicine Technology:Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
(Date:11/23/2009)... After suffering from women,s hair l...s growing back and she,s sharing her progress and ...her women through the release of her video diaries...ore and during her treatment. , ...hair loss sufferer Zsanett Siklosi has released t...
(Date:11/23/2009)...BORO,Pa.,Nov.23/PRNewswire-FirstCall/--InfoLogix,I...erprisemobilitysolutionsforthehealthcareandcommerc...residentofManagedServicesatSiemensHealthServices,h...areServices. ,, (Logo: http://www.newscom.com/c...sidentofStrategicHealthcareServicesforInfoLogix,Mr...
(Date:11/23/2009)...rters of cancer patients and survivors treated wit...that often become chronic conditions, hindering pa...entists at the University of Rochester Medical Cen...y experienced sleep troubles at nearly three times...as more prevalent in younger patients and those wi...
(Date:11/23/2009)... saw their odds drop by 63 percent with moderate-t...v. 23 (HealthDay News) -- Moderate-to-high intensi...y help reduce stroke risk in older men but not in ... almost 3,300 men and women, average age 69, in Ma...ring that time, there were 238 strokes among the p...
(Date:11/23/2009)...s up weaknesses of drug approval process in United.... 23 (HealthDay News) -- Problems with the popular...r heart attack, stroke and death, were known for y...he market in 2004, a new report says. , Contra... dangerous side effects were evident in 2000, a ye...
Breaking Medicine News(10 mins):Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3Health News:Insomnia prevalent among cancer patients who receive chemotherapy 2Health News:Vigorous Exercise Cuts Stroke Risk for Men, Not Women 2Health News: Vioxx Problems Known Years Before Recall 2Health News: Vioxx Problems Known Years Before Recall 3Health News: Vioxx Problems Known Years Before Recall 4
...al etiology is a challenging problem for the prima...act localization of lesion to either small or larg...ts. In tropical countries, where most of the popul...th good sensitivity and specificity. Small bowel e...
...(Nasdaq: ABAX ), a medical products company manu...nounced today that Clint Severson, chairman and ch...; Company,s Eleventh Annual Growth,Stock Conferenc...axis develops, manufactures and markets portable b...
...st about possible outcomes, study finds , ...jority of families of critically ill patients want...s even if it is uncertain, a new study finds. , ...Medicine , points out a definite rift in this area...
...National Glaucoma,Awareness Month, Glaucoma Resear...versary with a benefit at the historic Palace Hote...nt serves as the showcase for recent advances in,G...ucoma if nothing is,done. "Early detection and tre...
...ugh uphill climb if he,s to tackle Obama,s health ...medical records (EMR) are seeing the writing on th...ectronic medical billing is part of their softwa...rty solution offered by MPMsoft. , , Netalytics, ...
...ns New Products and Expanded Services in 2009 , ...mber 29, 2008 – Fisher Vista, LLC has report...in 2008, boosted by significant growth of its core...ervices Group , established in 2006, helped fuel t...
Other Medicine News:Health News:A new screening test for chronic abdominal pain 2Health News:Family Needs to Know When Patient Survival Is Uncertain 2Health News:Electronic Medical Billing: Going Electronic with Health Care Billing. 2Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 2Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 3
Nucleus Chopper - P. Koch
...n the new Magstim 200 monophasic transcranial stim...tise gathered in both the clinical and research en... will help further establish the new Magstim range...ular approach to design to complement any operatin...
...) is a surgical approach to glaucoma management th...pplication. The ciliary body (which produces aqueo...rior or posterior segment, through the endoscope i...urately identified utilizing endoscopy. This allow...
...) is a surgical approach to glaucoma management th...pplication. The ciliary body (which produces aqueo...rior or posterior segment, through the endoscope i...urately identified utilizing endoscopy. This allow...
Medicine Products: